Drug delivery systems patches

DeGrande, G. Benes, L. Horriere, E. Karsenty, H. Lacoste, C. McQuinn, R.L. Guo, J. Scherrer, R. Specialized oral mucosal drug delivery systems Patches. In Oral Mucosal Drug Delivery, Rathbone, M. J., Ed. Informa Healthcare New York, 1996. 

Sustained adhesion of the dosage form (tablet, patch) to the mucosa is an important first step to successful buccal delivery. The mucus plays an important role during this mucoadhe-sive process by buccal drug delivery systems. The interaction between the mucus and mucoadhesive polymers generally used in most dosage forms can be explained by theories summarized in Table 9.1. 

Transbuccal drug delivery systems are a new technology and spinoff of transdermal/topical drug delivery systems. Similar to monolithic adhesive matrix—type skin patches, transbuccal systems are designed to adhere to mucosal tissue in the oral cavity. A number of compounds are being evaluated in clinical studies.88... 

Woolfson, A. D., McCafferty, D. F., McCarron, P. A., and Price, FI. (1995), A bioadhesive patch cervical drug delivery system for the administration of 5-fluorouracil to cervical tissue, J. Controlled Release, 35,49-58. 

Scopolamine is available as a transdermal drug delivery system fisr prevention of motion sickness. When placed behind the ear the system delivers 0.5 mg of scopolamine for 3 days. Mydriasis and blurred vision can occur if scopolamine from the patch comes in contact with the eyes. 

Transdermal Slow absorption, rate may vary Transdermal delivery system (patch) is easy to use Some irritation by patch or drug Permeability of skin variable with condition, anatomic site, age, and gender... 

Merkle, H.P. Anders, R. Wermerskirchen, A. Mucoadhesive buccal patches for peptide delivery. In Bioadhesive Drug Delivery Systems Lenaerts, V., Gurney, R., Eds. CRC Press Boca Raton, PL, 1990 105. 

Formulation and/or development of advanced drug-delivery systems such as microencapsulated molecules, transdermal patches, or liposomes are frequently accomplished in the laboratory. However, large-scale production of these dosage forms may be problematic because the same conditions of manufacture may not be attainable or desirable in the plant setting. Consultation with process development personnel during the finalization of the prototype development phase is one way of minimizing scale-up difficulties. 

---